Pepticom raised $6.6 million in a Series A1 funding round led by Japan Israel High Tech Ventures 2 LP to accelerate the development of its oral IL-17 inhibitor program for autoimmune diseases.
Pepticom has successfully completed its Series A1 funding round, securing $6.6 million to advance its AI-driven peptide-based therapeutics. This funding will support the development of innovative treatments aimed at addressing autoimmune diseases through its cutting-edge drug discovery platform.
Who to call at Pepticom, and when
A new round usually means Pepticom is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Pepticom raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Pepticom, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pepticom. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Pepticom
Location
Jerusalem, Jerusalem District, Israel
About
Pepticom is a unique Artificial Intelligence (AI) platform company with disruptive technology for peptide discovery. The platform is based on research carried out in the Hebrew University and extensively developed further by the company.
Pepticom’s disruptive technology allows for the discovery of quantity and quality innovative peptides and other molecules at a fraction of the time and cost of the traditional laboratory discovery methods. The peptide discovered can be used as drugs, in agriculture and animal well-being.
Pepticom is engaged in various discovery projects such as ADAMA in the field of agriculture and with other big companies in the Pharmaceutical filed.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pepticom raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
JerusalemBiotechnologyHealth CareArtificial IntelligenceTherapeutics